Psychiatry Research: Neuroimaging
Volume 174, Issue 1 , Pages 76-80 , 30 October 2009

Decreased cardiac MIBG uptake, its correlation with clinical symptoms in dementia with Lewy bodies

  • Seiju Kobayashi

      Affiliations

    • Department of Neuropsychiatry, Sapporo Medical University, Sapporo, Japan
    • ,
  • Masaru Tateno

      Affiliations

    • Department of Neuropsychiatry, Sapporo Medical University, Sapporo, Japan
    • Corresponding Author InformationCorresponding author. Department of Neuropsychiatry, Sapporo Medical University, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 0608543, Japan. Tel.: +81 11 611 2111; fax: +81 11 644 3041.
    • ,
  • Hidetoshi Morii

      Affiliations

    • Department of Radiology, Sunagawa City Medical Center, Sunagawa, Japan
    • ,
  • Kumiko Utsumi

      Affiliations

    • Department of Psychiatry, Sunagawa City Medical Center, Sunagawa, Japan
    • ,
  • Toshikazu Saito

      Affiliations

    • Department of Neuropsychiatry, Sapporo Medical University, Sapporo, Japan

Received 15 November 2008 ,Revised 11 February 2009 ,Accepted 19 February 2009.

References 

  1. Algotsson A, Viitane M, Winblad B, Solders G. Autonomic dysfunction in Alzheimer's disease. Acta Neurologica Scandinavica. 1995;91:14–18
  2. Ballard C, Shaw F, McKeith I, Kenny R. High prevalence of neurovascular instability in neurodegenerative dementias. Neurology. 1998;51:1760–1762
  3. Braune S, Reinhardt M, Schnitzer R, Riedel A, Lucking CH. Cardiac uptake of [123 I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology. 1999;53:1020–1025
  4. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clinical Autonomic Research. 2001;11:351–355
  5. Estorch M, Camacho V, Paredes P, Rivera E, Rodríguez-Revuelto A, Flotats A, et al. Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. European Journal of Nuclear Medicine and Molecular Imaging. 2008;35:1636–1641
  6. Ganguly PK, Beamish RE, Dhalla KS, Innes IR, Dhalla NS. Norepinephrine storage, distribution, and release in diabetic cardiomyopathy. American Journal of Physiology. 1987;252:E734–739
  7. Gill JS, Hunter GJ, Gane G, Camm AJ. Heterogeneity of the human myocardial sympathetic innervation: in vivo demonstration by iodine123-labeled meta-iodobenzylguanidine scintigraphy. American Heart Journal. 1993;126:390–398
  8. Hanyu H, Shimizu S, Hirao K, Sakurai H, Iwamoto T, Chikamori T, et al. The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dementia and Geriatric Cognitive Disorders. 2006;22:379–384
  9. Hanyu H, Shimizu S, Hirao K, Kanetaka H, Iwamoto T, Chikamori T, et al. Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging. 2006;33:248–253
  10. Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation. 1988;78:1192–1199
  11. Horimoto Y, Matsumoto M, Akatsu H, Ikari H, Kojima K, Yamamoto T, et al. Autonomic dysfunction in dementia with Lewy bodies. Journal of Neurology. 2003;250:530–533
  12. Kobayashi S, Tateno M, Utsumi K, Takahashi A, Saitoh M, Morii H, et al. Quantitative analysis of brain perfusion spect in Alzheimer's disease using a fully automated regional cerebral blood flow quantification software, 3DSRT. Journal of the Neurological Sciences. 2008;264:27–33
  13. Kosaka K. Diffuse Lewy body disease in Japan. Journal of Neurology. 1990;237:197–204
  14. Kuzuhara S, Yoshimura M. Clinical and neuropathological aspects of diffuse Lewy body disease in the elderly. Advances in Neurology. 1993;60:464–469
  15. Lipsitz LA. Orthostatic hypotension in the elderly. The New England Journal of Medicine. 1989;321:952–957
  16. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–1872
  17. Merlet P, Valette H, Dubois-Randé JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. The Journal of Nuclear Medicine. 1992;33:471–477
  18. Minardo JD, Tuli MM, Mock BH, Weiner RE, Pride HP, Wellman HN, et al. Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation,. 1988;78:1008–1019
  19. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–2414
  20. Nakajima K, Taki J, Tonami N, Hisada K. Decreased 123I-MIBG uptake and increased clearance in various cardiac diseases. Nuclear Medicine Communications. 1994;15:317–323
  21. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 1999;67:189–194
  22. Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathologica. 2005;109:583–588
  23. Stanton MS, Tuli MM, Radtke NL, Heger JJ, Miles WM, Mock BH, et al. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine. Journal of the American College of Cardiology. 1989;14:1519–1526
  24. Suzuki M, Kurita A, Hashimoto M, Fukumitsu N, Abo M, Ito Y, et al. Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease. Journal of the Neurological Sciences. 2006;240:15–19
  25. Taki J, Yoshita M, Yamada M, Tonami N. Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Annals of Nuclear Medicine. 2004;18:453–461
  26. Tateno M, Utsumi K, Kobayashi S, Takahashi A, Saitoh M, Morii H, et al. Usefulness of a blood flow analyzing program 3DSRT to detect occipital hypoperfusion in dementia with Lewy bodies. Progress in Neuropsychopharmacology and Biology Psychiatry. 2008;32:1206–1209
  27. Tateno M, Kobayashi S, Utsumi K, Morii H, Fujii K. Quantitative analysis of the effects of donepezil on regional cerebral blood flow in Alzheimer's disease by using an automated program, 3DSRT. Neuroradiology. 2008;50:723–727
  28. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology . Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology. 1996;46:1470
  29. Tobes MC, Jaques S, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. The Journal of Nuclear Medicine. 1985;26:897–907
  30. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. The Journal of Nuclear Medicine. 1981;22:22–31
  31. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. Journal of the Neurological Sciences. 1998;155:60–67
  32. Yoshita M, Hayashi M, Hirai S. Decreased myocardial accumulation of 123I-meta-iodobenzylguanidine in Parkinson's disease. Nuclear Medicine Communications. 1998;19:137–142
  33. Yoshita M, Taki J, Yamada M. A clinical role for [(123I)] MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. Journal of Neurology, Neurosurgery, and Psychiatry. 2001;71:583–588
  34. Yoshita M, Taki J, Yokoyama K, Noguchi-Shinohara M, Matsumoto Y, Nakajima K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology. 2006;66:1850–1854

PII: S0925-4927(09)00050-X

doi: 10.1016/j.pscychresns.2009.02.006

Psychiatry Research: Neuroimaging
Volume 174, Issue 1 , Pages 76-80 , 30 October 2009

Article Tools

* Image Usage & Resolution